Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Published first ...

As previously reported, Evercore ISI initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Nimacimab is the ...

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available ...

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

Skye preparing to start Phase 2a glaucoma clinical trial in Q3San Diego, California-- (Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTC ...

Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several ...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Mar. 20, 2025 4:01 PM ET Skye Bioscience, Inc. (SKYE) ...

About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes.

Skye Bioscience, Inc. announced that it has granted stock options for 56,000 shares of its common stock to two new non-executive employees as part of its 2024 Inducement Equity Incentive Plan, in ...

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation ...